Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 4881 participants.

Also called NCT00991029

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 4,881 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT00991029
Other papers using this trial's data
  • Association of Black Race With Early Recurrence After Minor Ischemic Stroke or Transient Ischemic Attack: Secondary Analysis of the POINT Randomized Clinical Trial JAMA neurology, 2020-05-01 DOI, PubMed 32091536, PMC7042873 Not in the PMC Open Access subset.
  • Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA The New England journal of medicine, 2018-07-19 DOI, PubMed 29766750, PMC6193486 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Observed Versus Predicted Stroke Risk After Transient Ischemic Attack: A Post Hoc Analysis of a Randomized Clinical Trial Journal of the American Heart Association, 2026-03-03 DOI, PubMed 41717934, PMC13055761 In the PMC Open Access subset under CC BY-NC-ND.
  • Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial JAMA neurology, 2019-07-01 DOI, PubMed 31034032, PMC6583063 Not in the PMC Open Access subset.
  • Time Course for Benefit and Risk of Clopidogrel and Aspirin After Acute Transient Ischemic Attack and Minor Ischemic Stroke Circulation, 2019-08-20 DOI, PubMed 31238700
  • Time to treatment and disability attributed to index stroke in the POINT trial Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2024-11 DOI, PubMed 39222701, PMC13456534 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Finland, France, Germany, Mexico, New Zealand, Spain, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT00991029. Randomized; double masking; primary purpose treatment. Start 2010-05-28 (actual); primary completion 2018-04-09 (actual). Results posted on 2018-12-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
Acronym
POINT
Condition
Ischemic Attack, Transient
Intervention (Drug)
Clopidogrel
Intervention (Drug)
placebo
Lead sponsor
University of California, San Francisco (class: other)
Collaborator
Neurological Emergencies Treatment Trials Network (NETT) (class: research network)
Collaborator
Medical University of South Carolina (class: other)
Collaborator
The Emmes Company, LLC (class: industry)

Record details

Record id
cardio:ct-nct00991029
Content hash
7f6181388ac552ea12b48b7fa0884d645825481a20ca0dc19f005ea857f75166